My point was to compare multi-pronged attacks in HCV to HBV. I'm not sure if it's fair to compare ribavirin to a destabilizer, but it seemed somewhat analogous.
The ENTA de-stabilizer EDP-721 looks much better than ribavirin as second component of attack. Their mouse model shows a 3 log drop at day 14 with EDP-721. ENTA's antiviral EDP-514 achieved a 4 log drop. It remains to be seen what will happen in phase 1.
Am I understanding that there will be a presumed required 3rd component; a NUC?
Market Data 
Markets 
AI
